am 251 has been researched along with Parkinson Disease in 3 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "In models of Parkinson's disease, indirect-pathway eCB-LTD is absent but is rescued by a D2 receptor agonist or inhibitors of endocannabinoid degradation." | 1.34 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. ( Kreitzer, AC; Malenka, RC, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 1 |
| Bortolanza, M | 1 |
| Ferreira-Junior, NC | 1 |
| Wi, R | 1 |
| Chung, YC | 1 |
| Jin, BK | 1 |
| Kreitzer, AC | 1 |
| Malenka, RC | 1 |
3 other studies available for am 251 and Parkinson Disease
| Article | Year |
|---|---|
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Capsaicin; Disease Models, Animal; Dopaminerg | 2020 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Anim | 2007 |